These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18953376)

  • 41. The translational value of animal models in orphan medicines designations for rare paediatric neurological diseases.
    Duarte DM; Beatriz da Silva Lima M; Sepodes B
    Regul Toxicol Pharmacol; 2020 Dec; 118():104810. PubMed ID: 33122047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Orphan Drugs and Their Impact on Pharmaceutical Development.
    Attwood MM; Rask-Andersen M; Schiöth HB
    Trends Pharmacol Sci; 2018 Jun; 39(6):525-535. PubMed ID: 29779531
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adopting orphan drugs--two dozen years of treating rare diseases.
    Haffner ME
    N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
    [No Abstract]   [Full Text] [Related]  

  • 44. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases.
    Swinney DC
    Clin Pharmacol Ther; 2016 Oct; 100(4):339-41. PubMed ID: 27393380
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rare lung disease and orphan drug development.
    Spagnolo P; du Bois RM; Cottin V
    Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An interview on rare diseases and orphan medicines with Dr Daniel O'Connor, medical assessor at the Medicines and Healthcare products Regulatory Agency (MHRA), UK.
    O'Connor D
    Curr Med Res Opin; 2022 Feb; 38(2):159-160. PubMed ID: 35045782
    [No Abstract]   [Full Text] [Related]  

  • 49. Orphan drug legislation: lessons for neglected tropical diseases.
    Villa S; Compagni A; Reich MR
    Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C; Lampert A; Hoffmann GF; Ries M
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Access to medicines for orphan diseases: experience in the management of a case of Fasciola hepatica in Mumbai, Maharashtra, India.
    Thatte UM; Gogtay NJ; Sridharan K; Oak SN
    Natl Med J India; 2012; 25(4):234-5. PubMed ID: 23278785
    [No Abstract]   [Full Text] [Related]  

  • 52. Drug discovery and development for Huntington's disease - an orphan indication with high medical need.
    Heitz F; La Rosa S; Gonzalez-Couto E; Gaviraghi G; Terstappen GC
    IDrugs; 2008 Sep; 11(9):653-60. PubMed ID: 18763216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Introducing 'Health Vulnerability'. Towards a Human Right Claim for Innovative Orphan Drugs?
    Gennet É
    Eur J Health Law; 2020 Apr; 27(3):290-307. PubMed ID: 33652405
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges.
    Qiao L; Liu X; Shang J; Zuo W; Xu T; Qu J; Jiang J; Zhang B; Zhang S
    Orphanet J Rare Dis; 2022 Sep; 17(1):352. PubMed ID: 36088349
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Do we need authorized orphan drugs when compounded medications are available?
    Dooms M; Pincé H; Simoens S
    J Clin Pharm Ther; 2013 Feb; 38(1):1-2. PubMed ID: 22973866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Competing for public funding of medicines to treat rare disorders in New Zealand.
    Crausaz S
    Bull World Health Organ; 2015 Feb; 93(2):67. PubMed ID: 25883396
    [No Abstract]   [Full Text] [Related]  

  • 58. [Distribution of orphan drugs by the pharmacist of the Faculty of Veterinary Medicine].
    Tijdschr Diergeneeskd; 2004 Jul 15-Aug 1; 129(14-15):486. PubMed ID: 15344826
    [No Abstract]   [Full Text] [Related]  

  • 59. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
    Kumar Kakkar A; Dahiya N
    Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
    Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
    Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.